Last reviewed 2026-04-19 · How we verify

Bronchospasm

Approved treatments

• Proventil · Merck & Co.
• ProAir · Generic (originally Allen & Hanburys/GSK)
  Short-acting beta-2 adrenergic agonist (SABA) that relaxes bronchial smooth muscle, providing rapid relief of bronchospasm.
• Akovaz
  Akovaz works by releasing norepinephrine, a natural chemical in the body that helps to relieve symptoms of respiratory and allergic conditions.
• Levalbuterol · University of Aleppo
  Levalbuterol activates beta 2 -adrenergic receptors, increasing cyclic AMP and relaxing airway smooth muscles.
• Theophyllin · University of Bergen
• Atrovent
• Xopenex · Oak Pharms Inc
  Xopenex works by activating the beta-2 adrenergic receptor, leading to bronchodilation and relaxation of airway smooth muscle.
• Diphyllin
• Aminophyllin · University of Padova
• xopenex · Phoenix Children's Hospital

Competitive intelligence

For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:

• Bronchospasm patent landscape — cliff calendar, originator estates, attackable patents
• Bronchospasm treatment landscape brief
• Bronchospasm treatment updates RSS

Frequently asked questions about Bronchospasm

Related

• Treatment landscape: Bronchospasm patent cliff · Bronchospasm CI report
• Treatment: Proventil · Merck & Co.
• Treatment: ProAir · Generic (originally Allen & Hanburys/GSK)
• Treatment: Akovaz
• Treatment: Levalbuterol · University of Aleppo
• Treatment: Theophyllin · University of Bergen
• All diseases: Browse the disease index · Disease landscape hub

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing